CIK 0001438533
- Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- Operating
- EIN
- 262383102
- Phone
- +1 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $79,495,607
- in 10 filings, $79.5M under 10b5-1 plans
Net −$79,495,607. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-05-11 | ASELAGE STEVE Director | Sale | −2,575 | $21.92 | $56K | 146,919 |
| 2021-11-16 | ASELAGE STEVE Director | Sale | −31,800 | $29.39 | $935K | 149,494 |
| 2021-11-05 | ASELAGE STEVE Director | Exercise or conversion | +10,000 | $16.23 | $162K | 171,794 |
| 2021-11-05 | ASELAGE STEVE Director | Sale | −10,000 | $26.23 | $262K | 161,794 |
| 2021-11-05 | ASELAGE STEVE Director | Exercise or conversion · Employee stock option (right to buy) | −10,000 | 70,000 | ||
| 2021-11-02 | ASELAGE STEVE Director | Sale | −3,500 | $30.00 | $105K | 19,500 |
| 2021-11-01 | ASELAGE STEVE Director | Sale | −5,000 | $29.48 | $147K | 23,000 |
| 2021-10-07 | ASELAGE STEVE Director | Exercise or conversion | +60,000 | $16.23 | $974K | 249,794 |
| 2021-10-07 | ASELAGE STEVE Director | Sale | −28,000 | $26.23 | $734K | 221,794 |
| 2021-10-07 | ASELAGE STEVE Director | Sale | −32,000 | $26.26 | $840K | 189,794 |
| 2021-10-07 | ASELAGE STEVE Director | Exercise or conversion · Employee stock option (right to buy) | −60,000 | 80,000 | ||
| 2021-07-16 | ASELAGE STEVE Director | Gift | −3,000 | 161,794 | ||
| 2021-07-16 | ASELAGE STEVE Director | Gift | +3,000 | 28,000 | ||
| 2021-05-14 | ASELAGE STEVE Director | Grant or award | +3,000 | 189,794 | ||
| 2021-05-14 | ASELAGE STEVE Director | Grant or award · Stock option (right to buy) | +9,000 | 9,000 | ||
| 2021-05-11 | ASELAGE STEVE Director | Sale | −2,146 | $19.58 | $42K | 186,794 |
| 2021-04-16 | ASELAGE STEVE Director | Exercise or conversion | +10,000 | $16.23 | $162K | 198,940 |
| 2021-04-16 | ASELAGE STEVE Director | Sale | −10,000 | $26.23 | $262K | 188,940 |
| 2021-04-16 | ASELAGE STEVE Director | Exercise or conversion · Employee stock option (right to buy) | −10,000 | 140,000 | ||
| 2021-03-17 | ASELAGE STEVE Director | Exercise or conversion | +10,000 | $16.23 | $162K | 206,667 |
Page 1 of 5 · 92 trades